Clinical Trial

Quality of Care for Adolescent and Young Adult (AYA) Patients Living With Serious or Advanced Cancer

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
This record was submitted inadvertently and was not intended for registration, as NIH is not the responsible party and the study is not an applicable clinical trial. As PRS does not permit deletion, the record has been marked as withdrawn.
Summary
Background: Cancer among adolescents and young adults (AYAs) is on the rise, with nearly 90,000 AYAs diagnosed in the US each year. While most are cured, an estimated 15,000 AYAs die of cancer in the US annually creating profound suffering for those whose lives are cut short and for those who survive them. AYAs face unique challenges near the end of life (EOL). The tragic circumstances surrounding young lives cut short by cancer often provoke intensive efforts to prolong life, sometimes at the cost of comfort and quality. Patients, families, and even clinicians experience these deaths as tragic, a departure from the natural order of life in which each generation outlives the one before it. The current study is designed to ensure future efforts to improve care is guided by patient perspectives. The aims of the study are to 1) measure the quality of care received by adolescents and young adults (AYAs) living with advanced cancer using patient-centered quality measures, focusing specifically on potential unmet psychosocial, spiritual, and communication needs and 2) to assess disparities in end-of-life (EOL) care quality and barriers to care experienced by Black, Asian, and Hispanic AYAs. Our research will enable us to answer remaining critically unanswered questions and unmet needs about EOL care quality and barriers to care experienced by AYAs.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-04-04
notable Enrollment reduced: 70 -> 0 participants 2026-04-04
Trial Details
NCT Number NCT07484282
Lead Sponsor National Cancer Institute (NCI)
Conditions Cancer, Patients Living With Stage IV or Recurrent Cancer
Start Date 2026-04-07
Primary Completion 2029-04-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-03